Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Confe... ( SOUTH SAN FRANCISCO Calif. Aug. 7...)

Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008

Date:8/7/2008

SOUTH SAN FRANCISCO, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that William D. Young, CEO and Chairman, is scheduled to present an update on the company's business at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 3, 2008 at 11:30 a.m. (Eastern Time) at the Four Seasons Hotel in Boston, MA.

To access the live audio broadcast or the subsequent archived recording, log on to http://www.monogrambio.com and go to the investor relations section ("Investors/Media" tab) and click on the "Events & Webcasts" link provided on the sidebar menu on the page.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Contacts:

Alfred G. Merriweather

Chief Financial Officer

Tel: 650 624-4576

amerriweather@monogrambio.com

Jeremiah Hall

Feinstein Kean Healthcare

Tel: 415 677-2700

jeremiah.hall@fkhe
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
2. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
3. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
4. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
5. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
6. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
7. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
8. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
9. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
10. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
11. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology

Post Your Comments:

Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Confe...( SOUTH SAN FRANCISCO Calif. Aug. 7...)